{"product_id":"anikatherapeutics-pestle-analysis","title":"Anika PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic advantage with our PESTLE Analysis of Anika—concise, research-backed insights into the political, economic, social, technological, legal, and environmental forces shaping the company’s prospects; ideal for investors and strategists. Purchase the full report to get the complete, editable breakdown and actionable recommendations for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reimbursement Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpgovernment-led changes in medicare and medicaid reimbursement rates heavily influence adoption of anika orthopedic joint preservation products fee-for-service spending on musculoskeletal care totaled about making risk material to revenue.\u003e\u003cpas of late the shift toward value-based care tying medicare payments to models anika show superior clinical outcomes retain favorable pricing tiers and hospital formulary placement.\u003e\u003cpdecision-makers must track legislation that could limit or expand coverage for injectable viscosupplementation payer varies with medicaid programs in states restricting directly affecting addressable market and unit sales.\u003e\n\u003c\/pdecision-makers\u003e\u003c\/pas\u003e\u003c\/pgovernment-led\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade and Tariff Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnika’s international supply chain is exposed to US-China and US-EU trade tensions; by end-2025 average import duties on medical components rose to 8.2% vs 6.1% in 2023, raising COGS pressure. \u003c\/p\u003e\n\u003cp\u003eTariff-related delays increased lead times by 12% in 2025, adding an estimated $24m in logistics and compliance costs annually. \u003c\/p\u003e\n\u003cp\u003eStrategic planning must model scenarios for protectionist spikes and buffer 6–10% margin erosion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Oversight and Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe speed of Anika’s product approvals depends on FDA and EMA capacity and funding; in FY2024 the FDA received about $6.7B from user fees and appropriations while EMA’s 2024 budget was roughly €470M, and political shifts to cut or boost these budgets can shorten or extend review timelines by months to years. Anika’s regenerative pipeline progress is therefore directly exposed to political decisions that affect staffing, review backlogs and accelerated pathway availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability in Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegional conflicts and political instability in Europe and Asia can disrupt Anika’s expansion and distribution, with 2024 reports showing supply-chain delays increased by 18% in affected corridors and APAC elective surgery volumes down up to 12% year-over-year in hotspots.\u003c\/p\u003e\n\u003cp\u003ePolitical unrest shifts hospital priorities to emergency care, reducing demand for orthopedics—elective orthopedic procedures fell ~10% during 2022–2024 crises in key markets, pressuring revenue mix.\u003c\/p\u003e\n\u003cp\u003eMaintaining a diversified geographic footprint is critical; firms with \u0026gt;30% revenue diversification across regions showed 5–8% lower volatility in 2023–2024 earnings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupply-chain delays +18% in affected corridors (2024)\u003c\/li\u003e\n\u003cli\u003eElective orthopedics volumes down ~10–12% in hotspots (2022–2024)\u003c\/li\u003e\n\u003cli\u003eRevenue diversification (\u0026gt;30% cross-region) cut earnings volatility by 5–8% (2023–2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Funding for Aging Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment initiatives to manage aging health underpin demand for Anika’s hyaluronic acid pain solutions; OECD countries increased public health spending to 8.8% of GDP on average in 2023, with many allocating extra funds for musculoskeletal care.\u003c\/p\u003e\n\u003cp\u003eWHO estimates osteoarthritis affects 10% of men and 18% of women over 60 globally, and Medicare musculoskeletal spending in the US exceeded $240 billion in 2022, signaling sustained policy-driven market growth for mobility-improving treatments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOECD public health spend 2023: 8.8% GDP\u003c\/li\u003e\n\u003cli\u003eOsteoarthritis prevalence 60+: ~10% men, 18% women (WHO)\u003c\/li\u003e\n\u003cli\u003eUS musculoskeletal spend 2022: \u0026gt;$240B (Medicare-related)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy, reimbursement and regulatory shifts threaten Anika’s revenue, margins, and timelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolicy-driven reimbursement shifts, value-based care adoption (~30–40% Medicare tied to VBC by 2025), state-level Medicaid coverage limits (10–15 states restrict viscosupplementation in 2024), rising import duties (8.2% avg by end-2025) and regulatory capacity (FDA user fees ~$6.7B 2024; EMA budget ~€470M 2024) materially affect Anika’s revenue, margins and approval timelines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare VBC tie\u003c\/td\u003e\n\u003ctd\u003e30–40% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates restricting viscosupp.\u003c\/td\u003e\n\u003ctd\u003e10–15 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg import duties\u003c\/td\u003e\n\u003ctd\u003e8.2% (end-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA funding\u003c\/td\u003e\n\u003ctd\u003e$6.7B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Anika across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to pinpoint actionable threats and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Anika’s PESTLE into a compact, presentation-ready brief that teams can quickly reference in meetings or drop into slide decks for fast alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Impacts on Production Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025—US CPI averaging ~3.4% in 2024 and forecast ~3.0% in 2025—raises costs for specialized raw materials and energy used in hyaluronic acid synthesis, where input price spikes have exceeded 8-12% in some feedstocks.\u003c\/p\u003e\n\u003cp\u003eAnika must balance rising input costs against competitive pricing in its orthopedic and sports medicine portfolios while analysts track gross margin pressure; Q3 2025 scenario models show a potential 150–250 bps margin squeeze if costs cannot be passed on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Capital Allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAt end-2025 US benchmark rates stood near 5.25% after several Fed hikes, raising Anika’s effective borrowing costs and likely constraining debt-funded R\u0026amp;D and M\u0026amp;A, pushing management toward tighter capex and prioritizing near-term organic projects; a 100–200 bp swing materially alters NPV for long-term tissue-regeneration programs, while a stabilizing rate outlook could reopen capacity for bolder investments in breakthrough technologies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Healthcare Spending Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic health directly influences elective procedures like joint injections and sports-medicine surgeries that drive Anika’s revenue; US elective procedure volumes fell ~8-12% during the 2020–2021 COVID downturn and recovered with discretionary spending rising 6.4% in 2024 as real disposable income improved. During uncertainty patients defer non-essential treatments, causing cyclical demand swings—Medtronic reported comparable procedure volatility in 2022–24. Anika’s performance tracks disposable income and employment stability in its patient demographics, with US unemployment at 3.7% (2024) supporting gradual demand normalization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a global entity, Anika faces U.S. dollar volatility versus the euro and other currencies; a 10% USD appreciation in 2024 would reduce reported euro sales roughly proportionally and pressure export pricing in key EU markets.\u003c\/p\u003e\n\u003cp\u003eCurrency moves can swing reported international revenue and gross margins; Anika uses hedging (forward contracts covering up to 60% of forecasted FX exposure in 2024) and localized finance teams to shore up earnings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUSD vs EUR: 2024 avg ~1.08; 2025 YTD ~1.10\u003c\/li\u003e\n\u003cli\u003eHedging: ~60% coverage of FX exposure\u003c\/li\u003e\n\u003cli\u003eImpact: 10% USD move ≈ 10% reported sales change\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Dynamics in MedTech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe competition for biomedical engineers and clinical researchers has pushed median salaries up ~12% in 2024 vs 2021, with US median biomedical engineer pay ≈ $108,000 (BLS 2024), increasing Anika’s hiring costs and R\u0026amp;D wage bill.\u003c\/p\u003e\n\u003cp\u003eWith biotech\/MedTech vacancy rates near 3.2% in 2024 and turnover \u0026gt;15%, Anika faces a tight labor market to secure talent for HA-based innovation.\u003c\/p\u003e\n\u003cp\u003eRising wage expectations and specialized benefits (average S\u0026amp;S packages adding ~18% to base pay) materially raise general and administrative expenses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedian biomedical engineer salary ≈ $108,000 (BLS 2024)\u003c\/li\u003e\n\u003cli\u003eSector vacancy rate ~3.2% (2024)\u003c\/li\u003e\n\u003cli\u003eTurnover \u0026gt;15%; benefits add ~18% to payroll\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation, FX and rates squeeze HA margins amid demand rebound\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersistent 2024–25 inflation (US CPI ~3.4% in 2024; ~3.0% forecast 2025) raises HA feedstock costs 8–12%, risking 150–250 bps margin pressure; US rates ~5.25% end-2025 increase borrowing costs; elective procedure demand tied to disposable income (real disposable income +6.4% in 2024) supports recovery; USD vs EUR ~1.08 (2024 avg)–1.10 (2025 YTD), ~60% hedging.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003e2025 YTD\/End\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CPI\u003c\/td\u003e\n\u003ctd\u003e~3.4%\u003c\/td\u003e\n\u003ctd\u003e~3.0% (forecast)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~5.25% end-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHA feedstock spike\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReal disposable income\u003c\/td\u003e\n\u003ctd\u003e+6.4%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/EUR\u003c\/td\u003e\n\u003ctd\u003e~1.08\u003c\/td\u003e\n\u003ctd\u003e~1.10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX hedging\u003c\/td\u003e\n\u003ctd\u003e~60% coverage\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAnika PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Anika PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the layout, content, and structure visible in this preview are identical to the downloadable file you’ll get immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751697363321,"sku":"anikatherapeutics-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/anikatherapeutics-pestle-analysis.png?v=1772234137","url":"https:\/\/growthsharematrix.com\/products\/anikatherapeutics-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}